Medpace Holdings Balances Strong Q1 With Booking Risks

Medpace Holdings Inc ((MEDP)) has held its Q1 earnings call. Read on for the main highlights of the call.

Medpace Holdings delivered a solid first quarter, pairing double-digit revenue and EBITDA growth with strong cash generation and a sizable, converting backlog. Management’s tone was confident enough to reaffirm full-year guidance, yet cautious on the near- to medium-term as elevated cancellations, weaker booking metrics and softer RFP activity cast some doubt on the pace of future growth.

Strong Revenue Growth

Medpace posted Q1 2026 revenue of $706.6 million, up 26.5% year over year, or 25.8% in constant currency, underscoring robust demand for its clinical research services. The top-line performance reflects both ongoing momentum in existing programs and healthy conversion of backlog into revenue despite a tougher bookings backdrop.

Robust EBITDA Expansion

EBITDA climbed 25.9% from a year earlier to $149.4 million, or 28.6% on a constant currency basis, keeping pace with revenue growth. The EBITDA margin was broadly stable at 21.1% versus 21.2% a year ago, suggesting Medpace is managing cost pressures even as pass-through items push up the revenue base.

Healthy Net Bookings vs Prior Year

Net new business awards entering backlog reached $618.4 million, an increase of 23.7% year over year, indicating still-solid client demand. However, the net book-to-bill ratio was 0.88 as higher cancellations and deal timing offset strong awards, raising questions about the sustainability of recent growth rates.

Large Backlog with Near-Term Convertibility

Ending backlog stood at roughly $2.9 billion, up 2.9% from the prior year, providing meaningful revenue visibility. Management expects about $1.94 billion of that to convert to revenue in the next 12 months, and Q1 saw a healthy 23.3% of beginning backlog converted, supporting near-term growth.

Strong Cash Generation and Liquidity

Operating cash flow in Q1 was $151.8 million, underscoring the company’s ability to turn earnings into cash and fund growth internally. Medpace finished the quarter with $652.7 million in cash and a negative net DSO of 58.8 days, reflecting fast collections and a strong liquidity position.

Solid Per-Share and Net Income Performance

Net income rose 8.1% year over year to $123.9 million, supporting higher returns to equity holders despite tax headwinds. Diluted EPS increased to $4.28 from $3.67 a year earlier, reflecting both earnings growth and Medpace’s efficient capital structure.

Reaffirmed Guidance and Capital Flexibility

Management left its 2026 outlook for revenue, EBITDA, net income and EPS unchanged, signaling confidence that current momentum can offset booking volatility. The company also highlighted an existing share repurchase authorization of just over $800 million and indicated it will continue to deploy it over time, though buybacks are excluded from formal guidance.

Win Rate and Opportunity Quality

Executives emphasized that initial award notifications and the overall win rate remain strong, pointing to a still-competitive commercial position. They described the quality of opportunity flow as good and highlighted ongoing initiatives to improve pipeline conversion, which will be crucial given softer headline RFP volumes.

Elevated Cancellations and Book-to-Bill Pressure

Cancellations increased again in Q1, with backlog cancellations reaching their highest level in more than a year and directly pressuring growth metrics. As a result, the net book-to-bill ratio slipped to 0.88, reflecting both the heavier cancellation activity and softer gross bookings compared with recent periods.

Backlog Coverage Deterioration Beyond 1 Year

Management acknowledged that backlog coverage beyond the next 12 months has been eroding for six consecutive quarters, a notable strategic concern. This deterioration heightens the risk to sequential growth unless cancellations ease or Medpace can materially lift win rates and pipeline conversion in coming quarters.

Gross Bookings Weakness

Gross awards in the quarter were characterized as on the low end of recent experience, exacerbating the pressure from cancellations on overall backlog growth. The combination leaves Medpace with a strong near-term revenue base but increases the need for a rebound in new awards to sustain growth further out.

Net Income Growth Lagging EBITDA

While EBITDA grew at roughly 26%, net income rose only 8.1%, revealing a gap driven mainly by a higher effective tax rate. Investors will be watching whether tax headwinds persist or moderate, as they directly impact bottom-line growth and earnings quality relative to operating performance.

High Reimbursable Costs

Pass-through, or reimbursable, costs were elevated at about 44% of revenue, inflating reported revenue but weighing on margins given their lower profitability. Management expects these pass-through levels to decline later in the year as certain metabolic studies roll off, which could provide some margin relief.

RFP Activity Down

Requests for proposals were down both sequentially and year over year in Q1, hinting at potential near-term softness in new business inflows. Management downplayed the headline count and stressed opportunity quality, yet the decline adds another layer of uncertainty on top of rising cancellations.

Uncertainty from Cancellation Drivers

Cancellations were linked mainly to product performance issues, project reprioritizations and timing shifts, with oncology and cardiovascular trials most affected. While not driven by broad macro or consolidation factors, these dynamics cloud visibility into project conversion and could delay revenue realization from parts of the pipeline.

Forward-Looking Guidance and Outlook

The company’s reaffirmed 2026 guidance assumes a 19% to 20% effective tax rate and $27.5 million of interest income, with no assumed share repurchases, grounding expectations in current fundamentals. Underpinning this outlook are strong Q1 financials, a $2.9 billion backlog with substantial near-term convertibility and robust liquidity, though management signaled that sustained growth will hinge on improving bookings and easing cancellations.

Medpace’s latest earnings call painted a picture of a company executing well today yet navigating emerging headwinds for tomorrow. With strong revenue growth, solid margins and ample cash, the near-term story remains constructive, but investors will be closely watching bookings, backlog coverage and cancellation trends to gauge how durable the growth trajectory really is.